Navigation Links
VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
Date:9/18/2013

MARIETTA, Ga., Sept. 18, 2013 /PRNewswire/ -- VIVEX BIOMEDICAL, INC., a biomaterials manufacturer and developer, announced today that it has successfully completed its first round of private equity financing.  The financing involved an over-subscribed offering of the Company's preferred stock, generating $7.6 million in start-up capital. 

Tracy Anderson, President and CEO of Vivex, said, "We are grateful to our shareholders and investors.  They have provided us capital to grow our rapidly expanding biosciences portfolio while allowing the executive team to focus on the strategic execution and day to day operations.  We are excited about the future of Vivex."

Start-up capital will be used to refine current and develop new products, expand its team, and identify and pursue strategic partnerships and other opportunities.  The company's patented flagship products, currently in development, include the MIAMI stem cell and mimetic pattern implants and other protected Intellectual Property.  The company's core biomaterials include demineralized bone matrix, sponge, allograft, and calcium phosphate products backed by a proprietary cleansing process that sustains bioactivity.

About VIVEX BIOMEDICAL, INC.

Vivex commenced operations in 2013 following a spin-off of the biomaterials division of Amendia, Inc., a Marietta, Georgia spinal implant manufacturer, and has since experienced rapid growth.  In support of the biologics-oriented platform, Vivex is developing a strategic portfolio of revolutionary interactive implants that nurture and guide the body's regenerative responses for accelerated healing while minimizing recuperation. The company's soon to be released flagship products range from bioresonant mimetic implants that encourage and enhance response from the body, to a revolutionary undifferentiated adult stem cell line that retains the multi-lineage potential to repair virtually any tissue type.

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the federal security laws.  Forward-looking statements are only predictions and are not guarantees of performance.  You should not place undue reliance on any forward-looking statements.  

For more information, please visit the company's website at www.vivex.com or contact the company's General Counsel, Michael F. Rozmajzl, Esq., CPA., at 770.575.5221.  


'/>"/>
SOURCE VIVEX BIOMEDICAL, INC.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New Reporting Guidelines For Case Reports Presented At The Congress On Peer Review And Biomedical Publication And Published In Seven Medical Journals
2. Saladax Biomedical Announces Addition to Leadership Team
3. Funding Tomorrow's Biomedical Research: California Healthcare Institute Hosts Pipeline for Life, July 15
4. The Galien Foundation Celebrates Biomedical Innovation in Fourth Galien Forum
5. David Julius Wins 2013 Dr. Paul Janssen Award for Biomedical Research
6. BioMedical Life Systems, Inc. Launches New FDA Cleared Non-Prescription TENS Device
7. Ondine Biomedical CEO Carolyn Cross Appointed Treasurer of International Photodynamic Association
8. Arteriocyte announces Launch of Compass Biomedical
9. Regenesis Biomedical Names Scott Brooks Chief Executive Officer
10. Premier Biomedical CEO Interviewed by The Wall Street Transcript
11. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent ... entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 ... joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
(Date:10/7/2017)... Phoenix, Arizona (PRWEB) , ... ... ... than 15 years’ experience providing advanced instruments and applications consulting for microscopy ... the in-house expertise in application consulting, Nanoscience Analytical offers a broad range ...
Breaking Biology Technology:
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):